Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a Phase 2 study titled ‘A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)’. The study aims to assess the safety and efficacy of AMG 193, a drug designed to treat advanced NSCLC with MTAP deletions, a condition with limited treatment options.
AMG 193, the investigational drug in this study, is administered orally in film-coated tablet form. It is being tested for its effectiveness in treating MTAP-deleted advanced NSCLC, a specific genetic mutation in lung cancer patients.
The study follows an interventional design with a randomized, sequential intervention model. It is unmasked and primarily focused on treatment. The study is divided into two parts: dose evaluation and dose expansion, to determine the optimal dosing of AMG 193.
The study began on December 26, 2024, with primary completion expected soon. The last update was submitted on August 20, 2025. These dates are crucial as they indicate the study’s progress and potential timeline for results.
The outcome of this study could significantly influence Amgen’s stock performance, as successful results may enhance investor confidence and competitive positioning in the oncology market. Investors should watch for updates, as positive findings could impact the broader industry, particularly among competitors targeting similar genetic mutations.
The study is ongoing, with further details available on the ClinicalTrials portal.